PATH’s Kaslow to succeed Marks as head of vaccines at FDA

David Kaslow, CSO at PATH and head of the non-profit’s Center for Vaccine Introduction and Access, will succeed Peter Marks as the director of the Office of Vaccines Research and Review in FDA’s Center for Biologics Evaluation and Research (CBER), effective Oct. 11. Kaslow joined PATH in 2012 as director of its Malaria Vaccine Initiative, also supporting teams that developed vaccines for enteric and diarrheal diseases; for respiratory infections and maternal immunization; for emerging diseases, including Nipah and COVID-19; and for polio and human papillomavirus. Prior to joining PATH, he was a VP of vaccines and infectious disease at Merck & Co. Inc. (NYSE:MRK).

Marks took over at the office a year ago following the resignations of its director, Marion Gruber, and deputy director, Phil Krause, who say Marks ignored their opposition to the approval of COVID-19 vaccine boosters for all individuals who have received two doses of a COVID-19 vaccine. ...